---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003887"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:58:19.043919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics reports FY2023 net loss $14.3M ($3.95/share); cash $21.6M; IND cleared for APR-1051

## Summary
- Cash and equivalents $21.6M at Dec 31, 2023; combined with $16M Mar 2024 private placement funds into Q3 2025.
- Net loss FY2023 $14.3M ($3.95/basic share) vs $112.7M in FY2022 which included $76M acquired IPR&D charge.
- ATRN-119 Phase 1/2a dose escalation on track for 4Q 2024 completion; initial efficacy data expected H2 2024.
- FDA cleared IND for APR-1051 (WEE1 inhibitor); Phase 1 ACESOT-1051 trial to start H1 2024.
- Operating loss $15.5M in FY2023 vs $113.4M in FY2022; R&D expenses fell to $7.6M from $16.4M.

## SEC filing metadata
- accession: 0001558370-24-003887
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024003887/0001558370-24-003887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024003887/apre-20240326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003887
- JSON: https://secwatch.observer/filing/0001558370-24-003887.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.